DXR Stock Summary and Trading Ideas (Daxor - Closed End | NASDAQ:DXR)

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. The company operates as a single business segment centered on the development, commercialization, and support of its proprietary blood volume analysis technology used by healthcare providers.

Daxor - Closed End trades on the NASDAQ stock market under the symbol DXR.

As of October 2, 2026, DXR stock price declined to $10.62 with 8,231 million shares trading.

DXR has a beta of 0.47, meaning it tends to be less sensitive to market movements. DXR has a correlation of 0.02 to the broad based SPY ETF.

DXR has a market cap of $61.89 million. This is considered a Micro Cap stock.

In the last 3 years, DXR traded as high as $14.76 and as low as $6.55.

The top ETF exchange traded funds that DXR belongs to (by Net Assets): VTI.

DXR has underperformed the market in the last year with a price return of -24.1% while the SPY ETF gained +16.1%. DXR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +2.3% and -7.2%, respectively, while the SPY returned +3.6% and +1.0%, respectively.

DXR support price is $10.15 and resistance is $11.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DXR shares will trade within this expected range on the day.